BMJ 2016; 352 doi: (Published 19 January 2016) What is already known on this topic Patients’ preferences are a hallmark of patient centered care, but little is known about how wording of offers of testing can influence perceived preferences Opt-in and opt-out HIV testing have not been compared in a randomized controlled setting US guidelines endorse opt-out HIV testing, and Europe has seen a...
nam/aidsmap, Published: 26 January 2016 Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse...
ScienceDaily, December 23, 2015 In one of the most tightly controlled trials ever conducted of drugs used to treat sexually transmitted infections, researchers at the University of Alabama at Birmingham have confirmed that azithromycin remains effective in the treatment of urogenital chlamydia. In a study published Dec. 24 in the New England Journal of Medicine, the research team compared two of...
NAM , 02 December 2015 The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional...
Australian Federation of AIDS Organisations (AFAO), 01 October, 2015 The WHO Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, released 30 September, recommends that everyone diagnosed with HIV should be offered immediate antiretroviral therapy (ART), and all people at ‘substantial’ risk of HIV should be offered pre-exposure prophylaxis (PrEP)...
ABC: The Health Report, Monday 27 July 2015 5:50PM For people diagnosed with HIV, an effective vaccine is something of a holy grail. It would allow serodiscordant couples to manage the possibility of transmission, and improve outcomes for millions of HIV-positive cases, many of which are in sub-Saharan Africa. Vaccines have been tried before: two different HIV vaccines were tested in Thailand...